Neural cadherin overexpression is a predictive marker for early postoperative recurrence in hepatocellular carcinoma patients

Journal of Gastroenterology and Hepatology (Australia)

Volumn 23, Issue 7 PT1, 2008, Pages 1112-1118

  Seo, Dong Dae ^b   Lee, Han Chu ^a   Kim, Ha Jung ^a   Min, Hyun Ju ^a   Kim, Kang Mo ^a   Lim, Young Suk ^a   Chung, Young Hwa ^a   Lee, Yung Sang ^a   Suh, Dong Jin ^a   Yu, Eunsil ^a   Chun, Sun Young ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Inje University College of Medicine   (South Korea)

Author keywords

Epithelial cadherin; Hepatocellular carcinoma; Neural cadherin; Recurrence

Indexed keywords

NERVE CELL ADHESION MOLECULE; UVOMORULIN;

ADULT; ARTICLE; CANCER RECURRENCE; CLINICAL ASSESSMENT; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; EARLY DIAGNOSIS; FEMALE; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIODIAGNOSIS; UNIVARIATE ANALYSIS; UPREGULATION;

EID: 47649090335     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2007.05182.x     Document Type: Article

References (28)

1. Arias AM. Epithelial mesenchymal interactions in cancer and development. Cell 2001 105 : 425 31.
2. Perl AK, Wilgenbus P, Dahl U, Semb H, Christofori G. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 1998 392 : 190 3.
3. Umbas R, Isaacs WB, Bringuier PP et al. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res. 1994 54 : 3929 33.
4. Richmond PJ, Karayiannakis AJ, Nagafuchi A, Kaisary AV, Pignatelli M. Aberrant E-cadherin and alpha-catenin expression in prostate cancer: correlation with patient survival. Cancer Res. 1997 57 : 3189 93.
5. Mattijssen V, Peters HM, Schalkwijk L et al. E-cadherin expression in head and neck squamous-cell carcinoma is associated with clinical outcome. Int. J. Cancer 1993 55 : 580 5.
6. Vleminckx K, Vakaet L Jr, Mareel M, Fiers W, van Roy F. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 1991 66 : 107 19.
7. Frixen UH, Behrens J, Sachs M et al. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J. Cell Biol. 1991 113 : 173 85.
8. Gao ZH, Tretiakova MS, Liu WH, Gong C, Farris PD, Hart J. Association of E-cadherin, matrix metalloproteinases, and tissue inhibitors of metalloproteinases with the progression and metastasis of hepatocellular carcinoma. Mod. Pathol. 2006 19 : 533 40.
9. Liu J, Lian Z, Han S et al. Downregulation of E-cadherin by hepatitis B virus X antigen in hepatocellular carcinoma. Oncogene 2006 25 : 1008 17.
10. Hazan RB, Phillips GR, Qiao RF, Norton L, Aaronson SA. Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis. J. Cell Biol. 2000 148 : 779 90.
11. Nieman MT, Prudoff RS, Johnson KR, Wheelock MJ. N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression. J. Cell Biol. 1999 147 : 631 44.
12. Li G, Satyamoorthy K, Herlyn M. N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells. Cancer Res. 2001 61 : 3819 25.
13. Kozyraki R, Scoazec JY, Flejou JF et al. Expression of cadherins and alpha-catenin in primary epithelial tumors of the liver. Gastroenterology 1996 110 : 1137 49.
14. Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment. Liver Cancer Study Group of Japan. Ann. Surg. 1990 211 : 277 87.
15. Okamoto E, Kyo A, Yamanaka N, Tanaka N, Kuwata K. Prediction of the safe limits of hepatectomy by combined volumetric and functional measurements in patients with impaired hepatic function. Surgery 1984 95 : 586 92.
16. Vauthey JN, Lauwers GY, Esnaola NF et al. Simplified staging for hepatocellular carcinoma. J. Clin. Oncol. 2002 20 : 1527 36.
17. Nelson WJ, Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 2004 303 : 1483 7.
18. Tomita K, van Bokhoven A, van Leenders GJ et al. Cadherin switching in human prostate cancer progression. Cancer Res. 2000 60 : 3650 4.
19. Yanagimoto K, Sato Y, Shimoyama Y, Tsuchiya B, Kuwao S, Kameya T. Co-expression of N-cadherin and alpha-fetoprotein in stomach cancer. Pathol. Int. 2001 51 : 612 18.
20. Li G, Herlyn M. Dynamics of intercellular communication during melanoma development. Mol. Med. Today 2000 6 : 163 9.
21. Peluso JJ. Putative mechanism through which N-cadherin-mediated cell contact maintains calcium homeostasis and thereby prevents ovarian cells from undergoing apoptosis. Biochem. Pharmacol. 1997 54 : 847 53.
22. Ihara A, Koizumi H, Hashizume R, Uchikoshi T. Expression of epithelial cadherin and alpha- and beta-catenins in nontumoral livers and hepatocellular carcinomas. Hepatology 1996 23 : 1441 7.
23. Ouchi K, Matsubara S, Fukuhara K, Tominaga T, Matsuno S. Recurrence of hepatocellular carcinoma in the liver remnant after hepatic resection. Am. J. Surg. 1993 166 : 270 3.
24. Chen MF, Hwang TL, Jeng LB, Wang CS, Jan YY, Chen SC. Postoperative recurrence of hepatocellular carcinoma. Two hundred five consecutive patients who underwent hepatic resection in 15 years. Arch. Surg. 1994 129 : 738 42.
25. Matsumata T, Kanematsu T, Takenaka K, Yoshida Y, Nishizaki T, Sugimachi K. Patterns of intrahepatic recurrence after curative resection of hepatocellular carcinoma. Hepatology 1989 9 : 457 60.
26. Gwak GY, Yoon JH, Yu SJ et al. Anti-apoptotic N-cadherin signaling and its prognostic implication in human hepatocellular carcinomas. Oncol. Rep. 2006 15 : 1117 23.
27. Wei Y, Van Nhieu JT, Prigent S, Srivatanakul P, Tiollais P, Buendia MA. Altered expression of E-cadherin in hepatocellular carcinoma: correlations with genetic alterations, beta-catenin expression, and clinical features. Hepatology 2002 36 : 692 701.
28. Garcia S, Martini F, De Micco C et al. Immunoexpression of E-cadherin and beta-catenin correlates to survival of patients with hepatocellular carcinomas. Int. J. Oncol. 1998 12 : 443 7.